DNTH

Dianthus Therapeutics is a clinical-stage biotech developing complement and immune-pathway therapies for severe autoimmune diseases. Its lead candidate, claseprubart, is a selective C1s inhibitor engineered for convenient subcutaneous dosing, in mid-to-late-stage trials for generalized Myasthenia Gravis (gMG), CIDP, and MMN. The clinical news is genuinely encouraging: in September 2025 the company reported positive top-line Phase 2 MaGic data in gMG showing statistically significant, clinically meaningful improvements with a clean safety profile, held an end-of-Phase-2 FDA meeting, and plans to start a Phase 3 registrational trial in mid-2026 (top-line readout 2H2028). In March 2026 it announced an early 'GO' in the interim responder analysis of its Phase 3 CIDP CAPTIVATE trial — meaningful de-risking for an autoimmune-neurology pipeline.

The financial reality, however, is that this is a pre-revenue, cash-consuming enterprise. FY2025 'revenue' of just $2.04M is license-milestone income (including $6.0M of milestone payments under the Tenacia agreements recognized in the period), not product sales — and management states plainly it does 'not expect to generate any revenue from the sales of products in the foreseeable future.' The net loss widened to $162M as R&D spending rose 75.2% to $146M, and operating cash flow was -$129M. The balance sheet carries $493M of equity and $409M of current assets (cash plus marketable securities) against minimal liabilities (liabilities/equity 0.08x), but with that burn rate, additional dilutive financing is likely — share count already grew 38.4% YoY.